Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”) , a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2021 . All financial information is provided in U.S. dollars unless otherwise indicated.

1Q 2021 Financial Highlights (Unaudited)


($ thousands, except per share amounts)

Q1 2021

Q4 2020

% qoq
Change

Q1 2020

% yoy
Change

Total Revenue

$

260,320

$

230,253

13%

$

96,496

170%

Gross profit before impact of biological assets

$

128,467

$

110,595

16%

$

52,483

145%

Gross profit on cannabis sales (1)

$

128,030

$

109,625

17%

$

33,042

287%

Gross margin on cannabis sales (1)

49%

48%

43%

Adjusted EBITDA (1)

$

62,625

$

53,784

16%

$

20,006

213%

Net income (loss) attributable to Curaleaf Holdings Inc.

$

(17,211)

$

(35,274)

$

(15,089)

Net income (loss) per share – basic and diluted

$

(0.03)

$

(0.05)

$

(0.03)

(1)

See “Non-IFRS Financial and Performance Measures” below for more information regarding Curaleaf’s use of Non-IFRS financial measures and other reconciliations.

Earnings Call: Monday, May 10, 2021, at 5:00 P.M. ET

Conference ID # is 6935525

Replay ID # is 10155488

U.S. Callers: 1 (888) 317 6003

U.S. Replay: 1 (877) 344 7529

International Callers: 1 (412) 317 6061

International Replay (Toll): 1 (412) 317 0088

Canadian Callers: 1 (866) 284 3684

Canadian Replay: 1 (855) 669 9658

The teleconference will be rebroadcasted starting at 7:00 P.M. ET

on May 10, 2021 and will end at 7:00 P.M. ET on May 17, 2021

Joe Bayern , Chief Executive Officer of Curaleaf stated, “Curaleaf delivered record first quarter 2021 financial results with total revenue exceeding the high-end of our guidance range as we extended our U.S. leadership, all while creating a new foundation for future international growth opportunities. The stronger than expected first quarter performance drove record adjusted EBITDA as well as approximately 640 basis points of improvement in gross margin year-over-year. These impressive results reflect the leverage of the strategic investments we have made across the organization in cultivation, product innovation as well as expanding our branded retail and wholesale distribution channels. Curaleaf launched a range of innovative new products to our retail and wholesale channels during the quarter, including our new Select Squeeze THC-infused beverage enhancer which marked our most successful product launch ever and represented one of the cannabis industry’s widest national product launches to date. With our revenue projected to increase to $305 million to $315 million in the second quarter, we also expect to generate significant improvements in terms of achieving positive net income and positive operating cash flows in the back half of 2021.”

Boris Jordan , Executive Chairman of Curaleaf commented, “With the acceleration of cannabis liberalization momentum at the state and federal levels, Curaleaf’s prospects for growth in the United States have never been stronger. The recent approvals of adult-use cannabis in New Jersey and New York , which are states where Curaleaf has a leading market share, will unlock vast new markets, worth an estimated $2.1 billion and $5 billion in sales respectively. We raised approximately $300 million in new capital during the first quarter to help support our ability to scale for new adult-use markets while also allowing us to be opportunistic for highly attractive assets that further strengthen our position as the global cannabis market leader.”

First Quarter Highlights

  • Record revenue of $260 million , a growth of 170% YoY, above guidance of $250 million to $255 million .
  • Record adjusted EBITDA of $63 million , a growth of 213% YoY, and equivalent to a margin of 24%.
  • Raised net proceeds of $240.6 million in a public offering and net proceeds of $49.9 million from a tack-on to the existing secured credit facility.
  • Closed the quarter with 102 retail locations and 1,992 wholesale partner accounts.
  • Launched Select Squeeze, a THC-infused beverage enhancer, to date the widest cannabis product launch in the nation, available in 14 states.
  • Retail revenue grew by 14% sequentially, and 231% YoY, representing 72% of total revenue.
  • Wholesale revenue grew by 12% sequentially, and 254% YoY, representing 28% of total revenue.

Post First Quarter Highlights

  • Successfully closed the acquisition of EMMAC, Europe’s largest vertically integrated independent cannabis company, while securing $80 million in new capital into the European business subsidiary from a strategic investor to support future growth.
  • Opened four new stores since March 31, 2021 in Illinois and Pennsylvania , bringing total retail locations to 106.

Financial Results for the First Quarter Ended March 31, 2021

Total revenue increased by 170% to $260 million during the first quarter of 2021, compared to $96 million in the first quarter of 2020.

Revenue (Unaudited)

($ thousands)

Q1 2021

Q4 2020

Q1 2020

Retail revenue

$

187,677

$

164,932

$

56,633

Wholesale revenue

72,206

64,351

20,422

Management fee income

437

970

19,441

Total Revenue

$

260,320

$

230,253

$

96,496

Retail revenue increased by 231% to $188 million during the first quarter of 2021, compared to $57 million in the first quarter of 2020, representing 72% of total revenue. Growth in retail revenue was primarily due to strong organic growth across Curaleaf’s footprint, the opening of six new stores across Florida , Maine , and Pennsylvania , and the rapid acceleration of revenue growth in Arizona after the introduction of adult-use sales in January of 2021.

Wholesale revenue increased 254% to $72 million during the first quarter of 2021, compared to $20 million in the first quarter of 2020, representing 28% of total revenue. Growth in wholesale revenue was due primarily to the continued national expansion of the Select brand in both the Central and Northeastern markets including Massachusetts , New York , New Jersey , Maryland , Illinois , and Pennsylvania , and the successful launch of new products such as Select Squeeze, Select Essentials, and Select Fresh. It also resulted from strength of the Select brand in core Western markets including Arizona , California , and Oregon .

Gross Profit on Cannabis Sales (Unaudited)

($ thousands)

Q1 2021

Q4 2020

Q1 2020

Retail and wholesale revenues

$

259,883

$

229,283

$

77,055

Cost of goods sold

131,853

119,658

44,013

Gross profit on cannabis sales

$

128,030

$

109,625

$

33,042

Gross profit on cannabis sales was $128 million for the first quarter of 2021, compared to $33 million in the first quarter of 2020. Gross profit margin reached 49%, equivalent to a year-over-year increase of 636 basis points. The increase was primarily due to an expansion in operating capacity as well as improved efficiency in the Company’s cultivation and processing facilities.

Net Income (Loss)

($ thousands)

Q1 2021

Q4 2020

Q1 2020

Total Revenues

$

260,320

$

230,253

$

96,496

Gross profit

140,814

125,462

68,039

Income (Loss) from operations

33,705

20,627

4,993

Total other income (expense), net

(20,208)

(17,893)

(7,196)

Income tax benefit (expense)

(30,708)

(37,843)

(13,249)

Net loss

$

(17,211)

$

(35,109)

$

(15,089)

For the first quarter of 2021, net loss attributable to Curaleaf Holdings, Inc. was $17 million , compared to a net loss of $15 million in the first quarter of 2020. The net result was primarily impacted by an income tax provision of $31 million due to increased gross profit in certain of the Company’s subsidiaries that are subject to the restrictions of Section 280E of the Internal Revenue Code and, to a lesser degree, by an increase in the interest expense related to lease liabilities due to the expanded number of retail sites. Net loss for the quarter included approximately $6 million in one-time charges which mostly include expenses associated with the equity offering and debt raise. These effects were partially compensated by a significant increase in Income from Operations.

Adjusted EBITDA (Unaudited)

($ thousands)

Q1 2021

Q4 2020

Q1 2020

Net income (loss)

$

(17,211)

$

(35,109)

$

(15,452)

Interest expense, net

20,623

25,366

9,804

Income tax expense

30,708

37,843

13,249

Depreciation and amortization (1)

30,155

29,034

14,906

Share-based compensation

4,907

16,114

4,501

Other (income) expense

(415)

(7,473)

(2,608)

Change in fair value of biological assets

(12,347)

(14,867)

(15,556)

One time charges (2)

6,206

2,876

11,162

Adjusted EBITDA

$

62,625

$

53,784

$

20,006

(1)

Depreciation and amortization expense in Q1 2021, Q4 2020, and Q1 2020 include amounts charged to cost of goods sold on the statement of profits and losses.

(2)

One time charges in Q1 2021 mostly include expenses associated with the equity offering and debt raise.

Adjusted EBITDA was a record $63 million for the first quarter of 2021, compared to $20 million for the first quarter of 2020. The year-over-year increase in adjusted EBITDA was primarily driven by solid revenue growth combined with strong operating leverage.

Balance Sheet and Liquidity

As of March 31, 2021 , the Company had $315 million of cash and $340 million of outstanding debt net of unamortized debt discounts.

Capital Expenditures

During the first quarter of 2021, Curaleaf invested $31 million net in capital expenditures, mostly attributable to cultivation, processing, and retail sites development activities.

Shares Outstanding

As of March 31, 2021 and December 31, 2020 , our weighted average shares outstanding amounted to 682,041,420 and 557,192,899 shares, respectively.

As of March 31, 2021 and December 31, 2020 , our issued and outstanding SVS and MVS shares amounted to 686,409,852 and 663,801,845 shares, respectively.

Non-IFRS Financial and Performance Measures

In this press release Curaleaf refers to certain non-IFRS financial measures such as “Gross Profit on Cannabis Sales” and “Adjusted EBITDA”. These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers. The Company defines “Gross Profit on Cannabis Sales” as retail and wholesale revenues less cost of goods sold. “Adjusted EBITDA” is defined by Curaleaf as earnings before interest, taxes, depreciation and amortization less share-based compensation expense and one-time charges related to business development, acquisition, financing and reorganization costs. Curaleaf considers these measures to be an important indicator of the financial strength and performance of our business. We believe the adjusted results presented provide relevant and useful information for investors because they clarify our actual operating performance, make it easier to compare our results with those of other companies and allow investors to review performance in the same way as our management. Since these measures are not calculated in accordance with IFRS, they should not be considered in isolation of, or as a substitute for, our reported results as indicators of our performance, and they may not be comparable to similarly named measures from other companies. The following tables provide a reconciliation of each of the non-IFRS measures to its closest IFRS measure.

Consolidated Statements of Financial Position (Unaudited)

($ thousands)

March 31,

December 31,

2021

2020

Assets

Current assets:

Cash

$

314,591

$

73,542

Accounts receivable

33,750

28,830

Inventory, net

237,254

197,991

Biological assets

46,452

46,210

Assets held for sale

60,922

58,504

Prepaid expenses and other current assets

22,785

10,140

Current portion of notes receivable

3,723

2,645

Total current assets

719,477

417,862

Deferred tax asset

5,528

5,528

Notes receivable

2,004

2,000

Property, plant and equipment, net

259,109

242,855

Right-of-use assets, net

265,078

267,168

Intangible assets, net

781,111

797,401

Goodwill

469,837

470,144

Investments

16,264

16,264

Prepaid acquisition consideration

132,234

132,234

Other assets

30,726

35,135

Total assets

$

2,681,368

$

2,386,591

Liabilities and Shareholders’ Equity

Current liabilities:

Accounts payable

$

38,651

$

47,043

Accrued expenses

54,368

57,475

Income tax payable

110,147

79,649

Current portion of lease liability

16,382

15,710

Current portion of notes payable

4,193

6,500

Liabilities held for sale

12,775

7,181

Other current liabilities

1,454

6,568

Total current liabilities

237,970

220,126

Deferred tax liability

222,566

226,465

Notes payable

335,320

285,001

Lease Liabilities

270,948

270,495

Non-controlling interest redemption liability

2,694

2,694

Contingent consideration liability

1,898

1,898

Other long term liability

3,864

3,698

Total liabilities

1,075,260

1,010,377

Shareholders’ equity:

Share capital

2,021,980

1,754,412

Treasury shares

(5,208)

(5,208)

Reserves

(198,207)

(177,744)

Accumulated deficit

(211,856)

(194,645)

Total Curaleaf Holdings, Inc. shareholders’ equity

1,606,709

1,376,815

Redeemable non-controlling interest

(2,694)

(2,694)

Non-controlling interest

2,093

2,093

Total shareholders’ equity

1,606,108

1,376,214

Total liabilities and shareholders’ equity

$

2,681,368

$

2,386,591

Consolidated Statements of Profits and Losses (Unaudited)

($ thousands, except for share and per share amounts)

Three Months Ended

March, 31

2021

2020

Revenues:

Retail and wholesale revenues

$

259,883

$

77,055

Management fee income

437

19,441

Total revenues

260,320

96,496

Cost of goods sold

131,853

44,013

Gross profit before impact of biological assets

128,467

52,483

Realized fair value amounts included in inventory sold

(68,914)

(21,191)

Unrealized fair value gain on growth of biological assets

81,261

36,747

Gross profit

140,814

68,039

Operating expenses:

Selling, general and administrative

80,090

45,857

Share-based compensation

4,907

4,501

Depreciation and amortization

22,112

12,688

Total operating expenses

107,109

63,046

Income (Loss) from operations

33,705

4,993

Other income (expense):

Interest income

88

2,846

Interest expense

(12,151)

(10,492)

Interest expense related to lease liabilities

(8,560)

(2,158)

Other income (expense)

415

2,608

Total other income (expense), net

(20,208)

(7,196)

Income (Loss) before provision for income taxes

13,497

(2,203)

Income tax benefit (expense)

(30,708)

(13,249)

Net loss

(17,211)

(15,452)

Less: Net income (loss) attributable to non-controlling interest

(363)

Net loss attributable to Curaleaf Holdings, Inc.

$

(17,211)

$

(15,089)

Loss per share attributable to Curaleaf Holdings, Inc. – basic and diluted

$

(0.03)

$

(0.03)

Weighted average common shares outstanding – basic and diluted

682,041,420

507,700,498

About Curaleaf Holdings

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select and Grassroots provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States, Curaleaf currently operates in 23 states with 106 dispensaries, 23 cultivation sites and more than 30 processing sites, employing over 4,800 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com .

Contact Information

Investor Contact:
Curaleaf Holdings, Inc. Carlos Madrazo , SVP Head of IR & Capital Markets
ir@curaleaf.com

Media Contact:
Curaleaf Holdings, Inc. Tracy Brady , VP of Corporate Communications
media@curaleaf.com

Disclaimer

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of Canadian securities laws and United States securities laws (“forward-looking statements”). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management’s current beliefs, expectations or assumptions regarding the future of the business, plans and strategies, operational results and other future conditions of the Company. In addition, the Company may make or approve certain statements in future filings with Canadian securities regulatory authorities, in press releases, or in oral or written presentations by representatives of the Company that are not statements of historical fact and may also constitute forward-looking statements. All statements, other than statements of historical fact, made by the Company that address activities, events or developments that the Company expects or anticipates will or may occur in the future are forward-looking statements, including, but not limited to, statements preceded by, followed by or that include words such as “assumptions”, “assumes”, “guidance”, “outlook”, “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words and includes, among others, information regarding: its outlook for and expected operating margins, capital allocation, free flow cash and other financial results; growth of its operations via expansion, for the effects of any transactions; expectations for the potential benefits of any transactions; statements relating to the business and future activities of, and developments related to, the Company after the date of this press release, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company’s business, operations and plans; expectations that planned acquisitions will be completed; expectations regarding cultivation and manufacturing capacity; expectations regarding receipt of regulatory approvals; expectations that licenses applied for will be obtained; potential future legalization of adult-use and/or medical cannabis under U.S. federal law; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future. Forward-looking statements may relate to future financial conditions, results of operations, plans, objectives, performance or business developments. These statements speak only as at the date they are made and are based on information currently available and on the then current expectations. Holders of securities of the Company are cautioned that forward-looking statements are not based on historical facts but instead are based on reasonable assumptions and estimates of management of the Company at the time they were provided or made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the available funds of the Company and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the cannabis industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the cannabis industry; risks related to contracts with third-party service providers; risks related to the enforceability of contracts; reliance on the expertise and judgment of senior management of the Company, and ability to retain such senior management; risks related to proprietary intellectual property and potential infringement by third-parties; the concentrated voting control of the Company’s Chairman and the unpredictability caused by the capital structure; risks relating to the management of growth; increasing competition in the industry; risks inherent in an agricultural business; risks relating to energy costs; risks associated to cannabis products manufactured for human consumption including potential product recalls; reliance on key inputs, suppliers and skilled labor; cybersecurity risks; ability and constraints on marketing products; fraudulent activity by employees, contractors and consultants; tax and insurance related risks; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada ; risks related to future acquisitions or dispositions; sales by existing shareholders; limited research and data relating to cannabis; as well as those risk factors discussed under “Risk Factors” in the Company’s Annual Management, Discussion and Analysis dated March 11, 2021 , and in the Company’s Annual Information Form dated April 28, 2021 , and as described from time to time in documents filed by the Company with Canadian securities regulatory authorities. The purpose of forward-looking statements is to provide the reader with a description of management’s expectations, and such forward-looking statements may not be appropriate for any other purpose. In particular, but without limiting the foregoing, disclosure in this press release as well as statements regarding the Company’s objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. You should not place undue reliance on forward-looking statements contained in this press release. Such forward-looking statements are made as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The Company’s forward-looking statements are expressly qualified in their entirety by this cautionary statement.

This news release contains future-oriented financial information and financial outlook information (collectively, “FOFI”) about the Company’s prospective results of operations, production and production efficiency, commercialization, revenue and cash on hand, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set second in the above paragraph. FOFI contained in this document was approved by management as of the date of this document and was provided for the purpose of providing further information about the Company’s future business operations. The Company disclaims any intention or obligation to update or revise any FOFI contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law. Readers are cautioned that the FOFI contained in this document should not be used for purposes other than for which it is disclosed herein. The financial information reported in this news release is based on unaudited management prepared financial statements for the quarter ended March 31, 2021 . Accordingly, such financial information may be subject to change. Financial statements for the period will be released and filed under the Company’s profiles on SEDAR at www.sedar.com no later than May 12, 2021 . All financial information contained in this news release is qualified in its entirety with reference to such unaudited financial statements. While the Company does not expect there to be any material changes, to the extent that the financial information contained in this news release is inconsistent with the information contained in the Company’s unaudited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company’s unaudited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Service Provider has reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Cision View original content: http://www.prnewswire.com/news-releases/curaleaf-reports-record-first-quarter-2021-financial-and-operational-results-301287757.html

SOURCE Curaleaf Holdings, Inc.

News Provided by PR Newswire via QuoteMedia

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) announced today that it has been issued a Cease Trade Order (“ CTO ”) by the Ontario Securities Commission (the “ OSC ”) as it no longer expects to file the following periodic disclosure documents (collectively, the “ Documents ”) by June 11, 2021, as previously disclosed:

Keep reading... Show less

Adds two accomplished female directors to the Board

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the results of its Annual and Special Meeting of Shareholders held on June 10, 2021 (the “Meeting”). Each of the eight individuals nominated for election as a director of Trulieve at the Meeting were elected, including new nominees, Giannella Alvarez and Jane Morreau .

Keep reading... Show less

The National Football League (NFL) wants to know more about cannabis as a pain reliever, and it’s willing to put up an initial US$1 million for research.

Also this week, a cannabis operator announced plans to buy assets from a languishing producer.

Keep reading... Show less

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a new Florida dispensary, the Company’s 89th nationwide.

The dispensary will be located next to the Citrus Park Town Center and helps meet Trulieve’s goal of ensuring medical cannabis patients across Florida have safe, reliable access to the medications they rely on. The facility joins four other Tampa dispensaries, as well as several more in nearby Clearwater , St. Petersburg , and Largo.

Keep reading... Show less

On June 10, 2021, RCP23, LLC (the “Seller”), a private investment holding company controlled by Benjamin Kovler, CEO and Chairman of Green Thumb Industries Inc. (the “Issuer”) (CSE: GTII) (OTCQX: GTBIF), sold 1,666,667 Subordinate Voting Shares of the Issuer (the “Transferred Shares”) to a third-party qualified institutional buyer at a purchase price of US$30.00 per share in a private transaction.

“This transaction brings Green Thumb a new institutional shareholder who is aligned with management’s long-term vision,” said Manager of RCP23 Benjamin Kovler.  “RCP23 has historically sold shares on behalf of our legacy shareholders who invested prior to Green Thumb going public.”

Keep reading... Show less